XML 19 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue from Contracts with Customers
 9 Months Ended
Jan. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers Revenue from Contracts with Customers
Oncology Services Revenue
The following table represents disaggregated revenue for the three and nine months ended January 31, 2024 and 2023:
Three Months Ended
January 31,		Nine Months Ended January 31,
 2024202320242023
Pharmacology services$11,184 $12,119 $33,919 $38,355 
Other TOS revenue835 648 2,216 2,328 
Personalized oncology services— 6 18 116 
Total oncology services revenue$12,019 $12,773 $36,153 $40,799 
Other Translational Oncology Solutions ("TOS") revenue represents additional services provided to the Company's pharmaceutical and biotechnology customers, specifically flow cytometry services and software-as-a-service ("SaaS") provided via our Lumin Bioinformatics software ("Lumin").

Contract Balances
Contract assets include unbilled amounts typically resulting from revenue recognized in excess of the amounts billed to the customer for which the right to payment is subject to factors other than the passage of time. These amounts may not exceed their net realizable value. Contract assets are classified as current and included in accounts receivable. Contract liabilities consist of customer payments received in advance of performance and billings in excess of revenue recognized, net of revenue recognized from the balance at the beginning of the period and included in deferred revenue. Contract assets and liabilities are presented on the balance sheet on a net contract-by-contract basis at the end of each reporting period.